Dignitana obtains patent in the United States of America

Dignitana Proudly Announces that the United States Patent and Trademark Office (USPTO) has Granted a Patent to Dignitana, Further Protecting the Company´s Scalp Cooling Technology

Dignitana, a world leader in medical scalp cooling technology, has announced that it has been granted a patent by the USPTO. This patent has previously been granted in Europe, China, Korea and Japan, and now also in the United States with U.S. Patent number: 9,101,463. Dignitana has an active IP strategy and over the years worked to acquire rights in prioritized markets. Dignitana submitted the so-called PCT-application in 2008, and the decision by the USPTO provides Dignitana enhanced legal protection in the United States until 2031. This patent is part of Dignitana´s intellectual property (IP) portfolio, which consists of other patents, trademarks and industrial designs. The company’s portfolio provides a broad protection for its scalp cooling technology.

Dignitana’s scalp cooling system, DigniCap®, consists of a tight-fitting silicone cooling cap connected to a cooling and control unit. Coolant circulates through tunnels in the cap. The temperature in the cooling cap is monitored and automatically regulated during the entire cooling treatment, through a patented technology of sensors in the cooling cap. The scope of protection of this new patent covers the specific shaping of labyrinth paths in the cooling cap.

With this patent Dignitana has the right to exclude others from making, using, offering for sale, or selling the patented invention in, as well as importing into, the United States of America. To show to the market that Dignitana´s product is protected by this patent, the product or packaging will be marked with the patent number.

Jan Richardsson, CEO Dignitana AB (publ):

“Our scalp cooling system DigniCap®, for the reduction of chemotherapy related hair loss, is the only scalp-cooling device to have completed a formal trial for U.S. FDA approval. We are creating the necessary infrastructure for making DigniCap® widely available and accessible in the U.S. upon FDA Clearance. This legal protection is very important to have obtained at this point in time, as it gives us an additional competitive advantage in the U.S. market.

To further strengthen our IP strategy we will, with a grant received from ALMI / Vinnova, conduct a review of our IP strategy for preserving and utilizing our patents, trademarks, and industrial designs in the best way, thereby obtaining and maintaining government protection and strengthening our brand power.”

Media Contact:

Caren Browning                                                                                                           Jan Richardsson

King Company                                                                                                           Dignitana Chief Executive Officer

00 1 212 561-7464                                                                                                     0046 46 16 30 92

Caren.Browning@kingcompr.com                                                                            Jan.Richardsson@dignitana.se  

About Dignitana AB (publ)
Dignitana is a Swedish public company, based in Lund, and manufacturer of the medical cooling device DigniCap®. Dignitana is continuously researching and developing new uses for DigniCap®. Dignitana AB is listed on the OMX Nasdaq First North stock exchange and has appointed Erik Penser Bankaktiebolag as Certified Advisor. For more information visit www.dignitana.com

About the scalp cooling system DigniCap®
Dignitana’s core product - DigniCap® - is a patented scalp-cooling system that offers cancer patients the ability to keep their hair during chemotherapy. DigniCap® is developed to provide continuous cooling with high efficacy, safety and acceptable patient comfort.


About Us

Dignitana AB is the world leader in clinically superior scalp cooling technology. The company produces The DigniCap® Scalp Cooling System, a patented medical cooling device that offers cancer patients the ability to minimize hair loss during chemotherapy. FDA cleared since 2015, DigniCap provides continuous cooling with high efficacy, safety and patient comfort. Hailed internationally as a life-changing medical advancement for cancer patients, The DigniCap Scalp Cooling System was invented in 1999 by a Swedish Oncology nurse and has been available in Europe since 2001. Dignitana AB is listed on Nasdaq First North Growth Market in Stockholm with headquarters in Lund, Sweden and operations based in Dallas, Texas in the United States. Company subsidiaries are Dignitana, Inc. in the United States and Dignitana S.r.l. in Italy. Erik Penser Bank AB, Certified Adviser, +46 (0) 8 463 83 00 certifiedadviser@penser.se www.penser.se Learn more at www.dignitana.se and www.dignicap.com.


Documents & Links